nanoparticle-mrna-delivery-of-tfeb-clears-hepatic-fat-and-reduces-liver-fibrosis
Nanoparticle mRNA Delivery of TFEB Clears Hepatic Fat and Reduces Liver Fibrosis

Nanoparticle mRNA Delivery of TFEB Clears Hepatic Fat and Reduces Liver Fibrosis

Delivering messenger RNA to liver cells via lipid nanoparticles reverses hallmark features of metabolic dysfunction-associated steatotic liver disease in preclinical models, according to a study in Molecular Biomedicine. The team formulated ionizable lipid nanocarriers encapsulating synthetic transcripts encoding transcription factor EB, a master regulator governing cellular waste clearance and lipid catabolism. Evaluated in cultured human liver cells and male mice fed a steatohepatitis-inducing diet, the targeted genetic intervention elevated functional transcription factor levels in hepatic tissue. This increase stimulated autophagic flux, accelerated fatty acid oxidation, diminished intrahepatic lipid accumulation, and attenuated both inflammatory cell infiltration and fibrotic tissue remodeling without requiring systemic pharmacological inhibition of upstream metabolic regulators.

Metabolic dysfunction-associated steatotic liver disease represents a pervasive global health challenge, affecting approximately one-quarter of the adult worldwide population. The condition is characterized pathologically by excessive fat deposition exceeding five percent of hepatocytes without significant alcohol consumption or secondary causes. Left unchecked, simple steatosis frequently progresses along a pathological spectrum toward metabolic dysfunction-associated steatohepatitis, advanced hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. Despite close links to metabolic syndrome, obesity, and diabetes mellitus, pharmacological interventions remain limited. While selective thyroid hormone receptor-beta agonists have shown promise, and candidates such as GLP-1 receptor agonists and FGF analogs remain under evaluation, an acute need persists for targeted molecular strategies that directly correct hepatocellular metabolic derangements.

To evaluate prospective therapeutic targets, investigators analyzed transcriptomic datasets comprising 216 human liver biopsies across nonalcoholic fatty liver disease activity scores from zero to eight. Weighted gene co-expression network analysis grouped liver genes into fourteen distinct functional modules, clustering transcription factor EB within a turquoise regulatory module. Expression of this factor followed a biphasic trajectory during disease progression, rising in early steatosis, declining through intermediate stages, and displaying a modest secondary increase in late-stage cirrhosis. Functional enrichment profiling revealed that genes co-regulated with transcription factor EB, including VPS16, UBQLN4, and MCOLN1, coordinate lysosomal biogenesis, endosomal transport, and macroautophagy pathways. Because hepatic transcription factor activity correlates inversely with steatosis severity, restoring this master regulatory network presented an attractive strategy to stimulate natural lipid degradation.

Translating transcription factor EB activation into therapies has historically confronted severe pharmacological obstacles. Existing small-molecule activators, including ajugol and nuciferine, stimulate the factor through indirect mechanisms, specifically by inhibiting mechanistic target of rapamycin complex 1 or activating AMPK. Because the rapamycin-sensitive complex performs vital homeostatic functions across multiple tissues, systemic inhibition causes significant toxicities, including immunosuppression, hyperlipidemia, and hyperglycemia. To circumvent these off-target complications, the authors devised a genetic approach using lipid nanoparticles engineered for hepatic tropism. Validated clinically during the COVID-19 pandemic, systemically administered lipid nanoparticles exploit the fenestrated hepatic endothelium and an apolipoprotein E corona facilitating hepatocyte uptake. Furthermore, messenger RNA delivery is transient and non-integrating, avoiding insertional mutagenesis risks inherent to viral vectors.

Nanocarrier formulations were synthesized through microfluidic mixing of an organic lipid phase with an acidified aqueous nucleic acid phase. Microfluidic convergence with messenger RNA in 50 millimolar sodium citrate buffer at a three-to-one volumetric ratio yielded spherical nanoparticles with mean diameters between 114 and 115 nanometers. Dynamic light scattering confirmed monodisperse size distributions, while fluorometric dye-exclusion assays demonstrated encapsulation efficiencies approaching one hundred percent. Biocompatibility evaluations in human embryonic kidney cells confirmed negligible cytotoxicity, and erythrocyte lysis assays revealed less than five percent hemolysis, verifying that the lipid envelope preserves membrane integrity during circulatory transport.

Before evaluating therapeutic utility, researchers investigated the in vivo pharmacokinetic profile and tissue distribution of the nanocarriers in healthy mice. Tail-vein delivery of reporter nanoparticles containing firefly luciferase transcripts produced luminescence localized almost exclusively to the liver, confirming marked hepatic targeting. Time-course imaging indicated that reporter expression peaked at six hours following systemic injection, declined steadily over twenty-four hours, and became nearly undetectable at forty-eight hours. Intravenous injection of fifty-microgram reporter doses caused no significant alteration in serum liver enzymes or creatinine, confirming an absence of acute toxicity. Dose-titration studies established that a twenty-microgram dose transfected approximately sixty percent of liver cells. Translated transcription factor levels peaked at twenty-four hours and returned to baseline by seventy-two hours, establishing a bi-daily dosing schedule.

The cellular efficacy of the nanoparticle platform was initially validated in human Huh-7 hepatoma cultures. Cultured hepatocytes were treated with nanocarriers encapsulating transcripts encoding either wild-type transcription factor EB or a constitutively active mutant harboring a serine-to-alanine substitution at residue 211. At working concentrations of one microgram per milliliter, both formulations produced pronounced protein expression and elevated the ratio of lipidated LC3-II to LC3-I, consistent with activated autophagy. Quantitative PCR confirmed transcriptional upregulation of core autophagy genes, including SQSTM1, MAP1LC3, ATG7, and ATG10, alongside metabolic factors PPARA and PPARGC1A. When cells were subsequently challenged with palmitic acid to induce steatosis, both formulations downregulated lipogenic enzymes ACC and FASN, upregulated lipases LPL and HSL, and significantly decreased intracellular lipid accumulation in Oil Red O assays.

Preclinical in vivo therapeutic efficacy was evaluated in male C57BL/6J mice subjected to a two-week dietary regimen using a choline-deficient, L-amino acid-defined, high-fat diet. This nutritional protocol rapidly induces severe steatohepatitis, marked hepatic lipid accumulation, and progressive inflammatory injury without requiring genetic modifications. Animals received intravenous injections of twenty micrograms of control nanocarriers, wild-type transcription factor nanocarriers, or constitutively active mutant nanocarriers every two days throughout the dietary challenge. Serial monitoring demonstrated that body weights remained comparable across all groups, showing no gross systemic toxicity. Feeding the high-fat diet markedly elevated raw liver weights and liver index ratios in control animals, whereas both wild-type and mutant formulations significantly attenuated this pathological hepatomegaly. Furthermore, therapeutic administration restored autophagic flux without altering mTORC1 phosphorylation targets, confirming kinase-independent action.

Biochemical characterization of liver tissue demonstrated that nanoparticle therapy rebalanced hepatic lipid storage and systemic lipid transport. While serum total cholesterol levels remained indistinguishable among cohorts, administration of both wild-type and mutant transcripts substantially reduced intrahepatic triglyceride concentrations while increasing circulating serum triglycerides, reflecting enhanced hepatocellular lipid mobilization and lipoprotein secretion. Concurrently, wild-type nanocarrier treatment produced marked decreases in circulating serum alanine transaminase and aspartate transaminase concentrations, demonstrating meaningful mitigation of hepatic injury. Notably, while the constitutively active mutant reduced intrahepatic triglycerides to an equivalent extent, it failed to reduce circulating transaminases. This divergence suggests that permanent, unmitigated transcriptional activity may overtax lysosomal turnover mechanisms or disrupt intracellular organelles, illustrating that therapeutic activation of autophagic pathways operates within a tightly defined physiological safety window.

Histological assessments substantiated the broad therapeutic protection conferred by hepatic mRNA delivery against steatotic disease progression. Standard hematoxylin and eosin staining revealed widespread steatosis in untreated disease-model animals, which was visibly mitigated in treated cohorts, yielding significantly lower nonalcoholic fatty liver disease activity scores. Morphometric quantification of Sirius Red staining demonstrated a significant reduction in relative fibrotic area, confirming protection against early fibrotic remodeling. Fluorescent neutral lipid imaging using BODIPY dye confirmed pronounced reductions in intracellular lipid droplet accumulation throughout the hepatic parenchyma. Furthermore, immunofluorescent detection of macrophage marker F4/80 revealed that both wild-type and mutant interventions markedly reduced inflammatory macrophage infiltration within hepatic sinusoids, establishing that targeted restoration of lipid catabolism simultaneously quells downstream inflammatory recruitment and structural matrix scarring.

To decipher molecular mechanisms orchestrating these phenotypic recoveries, investigators performed comprehensive bulk RNA sequencing on hepatic tissue harvested from experimental cohorts. Exposure to the high-fat diet altered hundreds of hepatic transcripts, upregulating immune chemokines Ccr2, Ccr5, and integrin Itgam while substantially suppressing metabolic catabolism genes, most prominently carnitine palmitoyltransferase 1A and fibroblast growth factor 21. Treatment with wild-type and mutant nanoparticles concordantly reversed ninety-six downregulated genes and seventy-eight upregulated genes, shifting global transcriptomic profiles back toward healthy control signatures. Quantitative gene validation confirmed transcriptional reactivation of mitochondrial beta-oxidation driver Cpt1a and multiple acyl-CoA thioesterase isoforms, including Acot1, Acot2, Acot3, and Acot4. Concurrently, nanoparticle administration strongly suppressed interferon-inducible guanylate-binding proteins Gbp2, Gbp3, and Gbp5 alongside markers of fibrogenesis, highlighting a coordinated genetic reprogramming event.

Mechanistic explorations revealed that transcription factor EB coordinates metabolic recovery by transcriptionally activating the endocrine peptide fibroblast growth factor 21. Mining public chromatin immunoprecipitation datasets and performing ChIP-qPCR in cultured hepatocytes demonstrated that transcription factor EB binds directly to a coordinated lysosomal expression and regulation motif situated within the human FGF21 promoter. Dual-luciferase reporter assays using wild-type and mutated promoter constructs verified that transactivation depends strictly on this specific decameric motif. In Huh-7 cells, small interfering RNA silencing of FGF21 blunted the ability of nanocarriers to upregulate lipid catabolism markers or clear palmitic acid-induced lipid droplets. Furthermore, blocking peroxisome proliferator-activated receptor alpha with antagonist GW6471 partially abrogated lipid clearance, and treated mice exhibited elevated circulating serum FGF21 concentrations, solidifying the endocrine axis as a vital downstream effector.

Notwithstanding these encouraging preclinical outcomes, the authors emphasize several critical limitations that necessitate cautious interpretation. The experimental choline-deficient, L-amino acid-defined high-fat dietary model produces rapid liver steatosis and fibrosis but fails to replicate key systemic features of human disease, notably obesity and insulin resistance. Additionally, the therapeutic intervention spanned a brief duration of two weeks, leaving the durability and safety of sustained mRNA administration uncharacterized following treatment cessation. The research was conducted exclusively in young male mice, leaving potential sex-dependent dimorphisms in lipid metabolism and autophagic capacity unaddressed. Furthermore, while the critical role of downstream fibroblast growth factor 21 signaling was thoroughly dissected in vitro, genetic validation in animal knockouts remains necessary. Looking ahead, developing self-amplifying mRNA architectures or extended-release nanocarriers could lengthen hepatic expression windows, reducing the bi-daily dosing frequency required by standard transient transcripts.

Subject of Research: Preclinical lipid nanoparticle mRNA therapy targeting hepatic transcription factor EB to treat metabolic dysfunction-associated steatotic liver disease

Article Title: Lipid nanoparticle-mediated transcription factor EB mRNA delivery for the treatment of metabolic dysfunction-associated steatotic liver disease

Article References: Ju, W., Zhang, C., Zhang, T., Liu, Y., Wang, X., Zeng, L., Cao, Y., Lin, H., Li, O., Wang, P. G., He, Y., & Lu, H. (2026). Lipid nanoparticle-mediated transcription factor EB mRNA delivery for the treatment of metabolic dysfunction-associated steatotic liver disease. Molecular Biomedicine, 7(1), Article 220. https://doi.org/10.1186/s43556-026-00615-0

Image Credits: AI Generated

DOI: 10.1186/s43556-026-00615-0

Keywords: Transcription Factor EB, Lipid Nanoparticles, mRNA Delivery, Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis, Fibroblast Growth Factor 21, Autophagy Induction, Fatty Acid Oxidation, Carnitine Palmitoyltransferase 1A, Liver Fibrosis, Choline-Deficient Diet, CLEAR Box Element, Hepatic Macrophage Infiltration, Peroxisome Proliferator-Activated Receptor Alpha, DLin-MC3-DMA, Huh-7 Hepatocytes, Constitutive Activation S211A, Hepatic Triglycerides